Thalassemia, unspecified
ICD-10 D56.9 is a billable code used to indicate a diagnosis of thalassemia, unspecified.
Thalassemia is a group of inherited blood disorders characterized by reduced or absent synthesis of hemoglobin chains, leading to ineffective erythropoiesis and hemolytic anemia. The condition is primarily caused by genetic mutations affecting the alpha or beta globin genes, resulting in an imbalance in globin chain production. Patients with thalassemia may present with symptoms such as fatigue, pallor, and splenomegaly due to chronic hemolysis. The severity of thalassemia can vary widely, from asymptomatic carriers to individuals with severe anemia requiring regular blood transfusions. Diagnosis is typically confirmed through hemoglobin electrophoresis, complete blood count (CBC), and genetic testing. Management may include regular monitoring, blood transfusions, iron chelation therapy, and in some cases, hematopoietic stem cell transplantation. The unspecified nature of this code indicates that the specific type of thalassemia (alpha or beta) has not been determined, which can complicate treatment and management strategies.
Detailed lab results, family history, and treatment plans.
Management of patients with varying severity of thalassemia, including transfusion protocols.
Thorough documentation of hemoglobin levels and response to treatment is crucial.
Genetic testing results and family pedigree charts.
Counseling patients and families about inheritance patterns and risks.
Documentation of genetic counseling sessions and recommendations for family testing.
Used to evaluate anemia in patients suspected of having thalassemia.
Document the reason for the CBC and any relevant findings.
Hematologists may require additional tests based on CBC results.
Alpha thalassemia results from mutations in the alpha globin genes, while beta thalassemia is due to mutations in the beta globin genes. The clinical manifestations and severity can differ significantly between the two types.
